Cargando…

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data

Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maschio, Marta, Zarabla, Alessia, Maialetti, Andrea, Marchesi, Francesco, Giannarelli, Diana, Gumenyuk, Svitlana, Pisani, Francesco, Renzi, Daniela, Galiè, Edvina, Mengarelli, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247541/
https://www.ncbi.nlm.nih.gov/pubmed/30295079
http://dx.doi.org/10.1177/1534735418803758
_version_ 1783372497428676608
author Maschio, Marta
Zarabla, Alessia
Maialetti, Andrea
Marchesi, Francesco
Giannarelli, Diana
Gumenyuk, Svitlana
Pisani, Francesco
Renzi, Daniela
Galiè, Edvina
Mengarelli, Andrea
author_facet Maschio, Marta
Zarabla, Alessia
Maialetti, Andrea
Marchesi, Francesco
Giannarelli, Diana
Gumenyuk, Svitlana
Pisani, Francesco
Renzi, Daniela
Galiè, Edvina
Mengarelli, Andrea
author_sort Maschio, Marta
collection PubMed
description Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study. Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months. Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed. Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial.
format Online
Article
Text
id pubmed-6247541
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-62475412018-11-26 Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data Maschio, Marta Zarabla, Alessia Maialetti, Andrea Marchesi, Francesco Giannarelli, Diana Gumenyuk, Svitlana Pisani, Francesco Renzi, Daniela Galiè, Edvina Mengarelli, Andrea Integr Cancer Ther Research Articles Background and Aims: Peripheral neuropathy is a common complication of chemotherapy that can induce marked disability that negatively affects the quality of life in patients with multiple myeloma (MM). The aim of this study was to prevent the onset or the worsening of peripheral neuropathy in MM patients treated with bortezomib (BTZ), using a new nutritional neuroprotective compound. We report preliminary results of 18 out of 33 patients who completed the study. Methods: We administered a tablet of Neuronorm to patients, containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for the whole follow-up period. Neurological visit assessment, electroneurography, and evaluation scales were performed at baseline and after 6 months. Results: At 6 months, 8 patients had no chemotherapy-induced peripheral neuropathy, while 10 patients experienced chemotherapy-induced peripheral neuropathy of grade 1 according to the Common Terminology Criteria for Adverse Events, one of them with pain. Seventeen patients did not report painful symptoms; no limitation of functional autonomy and stability in quality of life domains explored was observed. Conclusions: Our results seem to indicate that early introduction of a neuroprotective agent in our patients with MM treated with BTZ could prevent the onset or the worsening of neuropathic pain, avoiding the interruption of the therapy with BTZ, and maintaining a good functional autonomy to allow normal daily activities. Despite the limitations due to the fact that this is a preliminary study, in a small population, with short follow-up, our data seem to indicate that the nutraceutical may have some potential to be considered for a future trial. SAGE Publications 2018-10-08 /pmc/articles/PMC6247541/ /pubmed/30295079 http://dx.doi.org/10.1177/1534735418803758 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Articles
Maschio, Marta
Zarabla, Alessia
Maialetti, Andrea
Marchesi, Francesco
Giannarelli, Diana
Gumenyuk, Svitlana
Pisani, Francesco
Renzi, Daniela
Galiè, Edvina
Mengarelli, Andrea
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title_full Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title_fullStr Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title_full_unstemmed Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title_short Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
title_sort prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and α-lipoic acid in patients with multiple myeloma: preliminary data
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247541/
https://www.ncbi.nlm.nih.gov/pubmed/30295079
http://dx.doi.org/10.1177/1534735418803758
work_keys_str_mv AT maschiomarta preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT zarablaalessia preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT maialettiandrea preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT marchesifrancesco preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT giannarellidiana preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT gumenyuksvitlana preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT pisanifrancesco preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT renzidaniela preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT galieedvina preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata
AT mengarelliandrea preventionofbortezomibrelatedperipheralneuropathywithdocosahexaenoicacidandalipoicacidinpatientswithmultiplemyelomapreliminarydata